JP6533466B2 - 抗菌性化合物、その合成およびその適用 - Google Patents

抗菌性化合物、その合成およびその適用 Download PDF

Info

Publication number
JP6533466B2
JP6533466B2 JP2015548841A JP2015548841A JP6533466B2 JP 6533466 B2 JP6533466 B2 JP 6533466B2 JP 2015548841 A JP2015548841 A JP 2015548841A JP 2015548841 A JP2015548841 A JP 2015548841A JP 6533466 B2 JP6533466 B2 JP 6533466B2
Authority
JP
Japan
Prior art keywords
bacteria
group
boc
compound
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015548841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504330A5 (https=
JP2016504330A (ja
Inventor
ハルダル，ジャヤンタ
ゴーシュ，チャンドラディシュ
ベラグラ マンジュナス，グータム
ベラグラ マンジュナス，グータム
アッカペッディ，パドマ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Health
Jawaharial Nehru Centre for Advanced Scientific Research
Original Assignee
UK Secretary of State for Health
Jawaharial Nehru Centre for Advanced Scientific Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UK Secretary of State for Health, Jawaharial Nehru Centre for Advanced Scientific Research filed Critical UK Secretary of State for Health
Publication of JP2016504330A publication Critical patent/JP2016504330A/ja
Publication of JP2016504330A5 publication Critical patent/JP2016504330A5/ja
Application granted granted Critical
Publication of JP6533466B2 publication Critical patent/JP6533466B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015548841A 2012-12-18 2013-12-18 抗菌性化合物、その合成およびその適用 Expired - Fee Related JP6533466B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN5299/CHE/2012 2012-12-18
IN5299CH2012 2012-12-18
PCT/IB2013/061090 WO2014097178A1 (en) 2012-12-18 2013-12-18 Antimicrobial compounds, their synthesis and applications thereof

Publications (3)

Publication Number Publication Date
JP2016504330A JP2016504330A (ja) 2016-02-12
JP2016504330A5 JP2016504330A5 (https=) 2017-01-26
JP6533466B2 true JP6533466B2 (ja) 2019-06-19

Family

ID=54148251

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015548841A Expired - Fee Related JP6533466B2 (ja) 2012-12-18 2013-12-18 抗菌性化合物、その合成およびその適用

Country Status (9)

Country Link
US (1) US9783490B2 (https=)
EP (1) EP2934563B1 (https=)
JP (1) JP6533466B2 (https=)
CN (1) CN104981249B (https=)
AU (1) AU2013365769B2 (https=)
BR (1) BR112015014391B1 (https=)
CA (1) CA2894202A1 (https=)
HK (1) HK1210437A1 (https=)
WO (1) WO2014097178A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105566149B (zh) * 2016-03-02 2017-05-24 郑州大学 具有抗菌活性的查尔酮阳离子抗菌肽模拟物及其制备方法
CN106995384B (zh) * 2017-04-21 2018-12-11 郑州大学 具有抗菌活性的二烷基阳离子两亲性抗菌肽模拟物及其制备方法
US20200354413A1 (en) 2017-12-15 2020-11-12 Dana-Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59309867D1 (de) 1992-09-03 1999-12-16 Boehringer Ingelheim Pharma Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
US5654451B1 (en) * 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
AU1441195A (en) * 1993-12-30 1995-07-17 Smithkline Beecham Corporation Phenylmethyl hexanamides, and the use thereof
US5663148A (en) 1994-07-12 1997-09-02 Abbott Laboratories Anaphylatoxin receptor ligands containing lipophilic residues
US6071890A (en) * 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
DE69612962T2 (de) * 1995-12-12 2001-11-15 Taiho Pharmaceutical Co. Ltd., Tokio/Tokyo Epoxysuccinamid-derivate oder deren salze und medikamente die diese enthalten
CA2217550A1 (en) * 1996-10-22 1998-04-22 F. Hoffmann-La Roche Ag Cationic lipids for gene therapy
BR9813554A (pt) * 1997-12-12 2001-07-24 Fuji Yakuhin Kogyo Kk Composto, uso do mesmo, processo para produzi-lo, composição farmacêutica ou veterinária, e, inibidor de metaloproteinase
WO2001040198A2 (fr) * 1999-11-30 2001-06-07 Aventis Pharma S.A. Derives macrocycliques de l'acide hydroxamique et leur utilisation en tant qu'antimicrobiens
JP2002161084A (ja) * 2000-11-28 2002-06-04 Sumitomo Pharmaceut Co Ltd 複素環誘導体
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
GB0512751D0 (en) * 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
US8097582B2 (en) 2006-05-09 2012-01-17 Neobiotics Ab Peptide derivatives useful as antimicrobial agents and for treating wounds
AU2007304847A1 (en) * 2006-10-04 2008-04-10 Inimex Pharmaceuticals, Inc. Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
EP2091917A1 (en) * 2006-12-11 2009-08-26 Wyeth a Corporation of the State of Delaware Ion channel modulators
CN102757477B (zh) * 2011-04-27 2014-09-03 首都医科大学 烯丙基半胱氨酰氨基酸甲酯衍生物及其合成方法和应用
EP2709619B1 (en) * 2011-05-16 2017-10-11 Cellceutix Corporation Compounds for use in treatment of mucositis

Also Published As

Publication number Publication date
US9783490B2 (en) 2017-10-10
AU2013365769B2 (en) 2018-03-15
CA2894202A1 (en) 2014-06-26
CN104981249B (zh) 2018-06-19
US20150329478A1 (en) 2015-11-19
EP2934563A1 (en) 2015-10-28
EP2934563B1 (en) 2020-07-08
BR112015014391A2 (pt) 2017-07-11
WO2014097178A1 (en) 2014-06-26
CN104981249A (zh) 2015-10-14
AU2013365769A1 (en) 2015-07-02
JP2016504330A (ja) 2016-02-12
BR112015014391B1 (pt) 2020-11-03
HK1210437A1 (en) 2016-04-22
EP2934563A4 (en) 2016-08-17

Similar Documents

Publication Publication Date Title
EP3594223B1 (en) Treatment of biofilms
RU2472805C2 (ru) Антибиотические пептиды
US11325955B2 (en) Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
JP2004501166A (ja) 化学修飾ペプチド、組成物、並びに製造方法および使用
Wang et al. Design and synthesis of 3-hydroxy-pyridin-4 (1 H)-ones–ciprofloxacin conjugates as dual antibacterial and antibiofilm agents against Pseudomonas aeruginosa
Qian et al. H 2 S-releasing amphiphilic dipeptide hydrogels are potent S. aureus biofilm disruptors
Gou et al. Bio-inspired peptide decorated dendrimers for a robust antibacterial coating on hydroxyapatite
JP6533466B2 (ja) 抗菌性化合物、その合成およびその適用
Li et al. Synthesis and bioactivities of new N-terminal dipeptide mimetics with aromatic amide moiety: Broad-spectrum antibacterial activity and high antineoplastic activity
JP2004501167A (ja) Ｂｕｒｋｈｏｌｄｅｒｉａｃｅｐａｃｉａの処理のためのペプチド、組成物および方法
JP2021178855A (ja) ヒストンデアセチラーゼの阻害剤としての大環状分子のチオエステルプロドラッグ
AU2012338461B2 (en) Cationic antibacterial composition
WO2019079759A1 (en) ANTI-PERSISTENCE AND ANTI-VIRULENCE COMPOUNDS WITH BROAD SPECTRUM
CN107106533B (zh) 用于治疗微生物感染的增效组合物
JP2018530738A (ja) 緑膿菌阻害化合物
Singh et al. Design, synthesis and biological profiling of novel phenothiazine derivatives as potent antitubercular agents
JPH10316666A (ja) 新規ベンズオキサジンジオン誘導体、その製造方法及びその使用方法
US9738684B2 (en) N-terminally modified linear and branched polyamine conjugated peptidomimetics as antimicrobials agents
TW201002321A (en) Pneumonia treatment
Erol et al. Synthesis, antimicrobial and in silico studies of new 2.5-disubstituted benzoxazole derivative
War et al. Design, synthesis and molecular docking studies of some morpholine linked thiazolidinone hybrid molecules
CN108078982A (zh) 脯氨酸衍生物在制备β-内酰胺酶抑制剂中的用途
Hachim et al. Design, Molecular Docking, Synthesis, and Antimicrobial Evaluation of new Dipeptide derivatives of Ceftizoxime sodium
WO2025240758A1 (en) Staphylococcus hominis daptide antibiotics, derivatives thereof, and methods of treatment
HK40129190A (zh) 用於处置或预防神经病理性疼痛和/或炎性疼痛的环状肽衍生物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180406

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181105

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20181207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190515

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190524

R150 Certificate of patent or registration of utility model

Ref document number: 6533466

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees